白雲山(00874.HK)與花城簽訂新持續關連交易協議
格隆匯10月28日丨白雲山(00874.HK)公佈,鑑於該集團與花城簽訂的現有持續關連交易協議即將於2019年12月31日到期,該集團已於2019年10月28日與花城簽訂一份兩年期的新持續關連交易協議,期限於2020年1月1日開始至2021年12月31日止。
該公司附屬企業或花城下采購訂單,或簽訂具體的勞務合同或加工合同時同類產品或服務的當前市價乃根據該集團按公平原則自中國獨立第三方供應同類產品或服務的價格按一般商業條款及於該集團日常業務過程中釐定。
據悉,花城是一家於中國成立的公司,其主要業務為製造醫藥產品及由廣藥集團全資擁有。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.